We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche
Read MoreHide Full Article
Recursion Pharmaceuticals, Inc. (RXRX - Free Report) announced that it has entered into a new collaboration with Genentech, a wholly-owned subsidiary of Swiss pharma giant Roche (RHHBY - Free Report) , to advance novel medicines in areas of neuroscience and oncology indication. The deal is worth several billion dollars.
Per the agreement, Recursion is entitled to receive an upfront payment of $150 million and additional performance-based milestone payments. The company will work with R&D units of both Roche and Genentech in order to leverage technology-enabled drug discovery through the recursion operating system for identifying novel targets and advance medicines in neuroscience and oncology indications.
Under the terms of the agreement, Roche and Genentech together may start up to 40 programs. Upon successful development and commercialization, each of these programs might yield more than $300 million for Recursion as sales-based milestone payments as well as tiered royalties on net sales.
With this collaboration, the companies are looking to build a model of technology-driven drug discovery, and develop medicines against novel targets in neuroscience and oncology indications.
Shares of Recursion were up 12.1% on Tuesday following the announcement of the news. The stock has plunged 31.4% in the past six months compared with the industry’s decrease of 12.5%.
Image Source: Zacks Investment Research
We remind investors that Recursion started trading on the NASDAQ stock exchange following its initial public offering on April 16, 2021.
The company’s clinical pipeline currently consists of several pipeline candidates being developed in early to mid-stage studies for treating different types of indications.
Recursion plans to initiate a parallel-group, two-stage, phase II/III study evaluating REC-2282 for the potential treatment of NF2 meningiomas in early 2022. The company also plans to initiate a phase II study on another candidate, REC-994, for treating cerebral cavernous malformation early next year.
The company is looking to start two separate phase II study on REC-4881 and REC-3599 for the treatment of familial adenomatous polyposis and GM2 gangliosidosis, respectively, in the first half of 2022.
Please note that Recursion has collaboration with Bayer AG (BAYRY - Free Report) to discover small-molecule drug candidates with the potential to treat fibrotic diseases.
Earlier this month, Recursion expanded its existing strategic collaboration with Bayer to include the former’s inferential search capabilities, enabling Bayer to accelerate the work on fibrotic diseases.
Zacks Rank & Stock to Consider
Recursion currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the same sector is Endo International plc , which has a Zacks Rank #1 (Strong Buy) at present.You can see the complete list of today’s Zacks #1 Rank stocks here.
Endo International’s earnings estimates have been revised 24% upward for 2021 and 10.3% upward for 2022 over the past 60 days.
Endo International’s earnings have surpassed estimates in each of the trailing four quarters.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche
Recursion Pharmaceuticals, Inc. (RXRX - Free Report) announced that it has entered into a new collaboration with Genentech, a wholly-owned subsidiary of Swiss pharma giant Roche (RHHBY - Free Report) , to advance novel medicines in areas of neuroscience and oncology indication. The deal is worth several billion dollars.
Per the agreement, Recursion is entitled to receive an upfront payment of $150 million and additional performance-based milestone payments. The company will work with R&D units of both Roche and Genentech in order to leverage technology-enabled drug discovery through the recursion operating system for identifying novel targets and advance medicines in neuroscience and oncology indications.
Under the terms of the agreement, Roche and Genentech together may start up to 40 programs. Upon successful development and commercialization, each of these programs might yield more than $300 million for Recursion as sales-based milestone payments as well as tiered royalties on net sales.
With this collaboration, the companies are looking to build a model of technology-driven drug discovery, and develop medicines against novel targets in neuroscience and oncology indications.
Shares of Recursion were up 12.1% on Tuesday following the announcement of the news. The stock has plunged 31.4% in the past six months compared with the industry’s decrease of 12.5%.
We remind investors that Recursion started trading on the NASDAQ stock exchange following its initial public offering on April 16, 2021.
The company’s clinical pipeline currently consists of several pipeline candidates being developed in early to mid-stage studies for treating different types of indications.
Recursion plans to initiate a parallel-group, two-stage, phase II/III study evaluating REC-2282 for the potential treatment of NF2 meningiomas in early 2022. The company also plans to initiate a phase II study on another candidate, REC-994, for treating cerebral cavernous malformation early next year.
The company is looking to start two separate phase II study on REC-4881 and REC-3599 for the treatment of familial adenomatous polyposis and GM2 gangliosidosis, respectively, in the first half of 2022.
Please note that Recursion has collaboration with Bayer AG (BAYRY - Free Report) to discover small-molecule drug candidates with the potential to treat fibrotic diseases.
Earlier this month, Recursion expanded its existing strategic collaboration with Bayer to include the former’s inferential search capabilities, enabling Bayer to accelerate the work on fibrotic diseases.
Zacks Rank & Stock to Consider
Recursion currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the same sector is Endo International plc , which has a Zacks Rank #1 (Strong Buy) at present.You can see the complete list of today’s Zacks #1 Rank stocks here.
Endo International’s earnings estimates have been revised 24% upward for 2021 and 10.3% upward for 2022 over the past 60 days.
Endo International’s earnings have surpassed estimates in each of the trailing four quarters.